About: Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan
Creator	Sanguinetti, Maurizio Mikulska, Malgorzata Viscoli, Claudio Furfaro, Elisa Di Grazia, Carmen Angelucci, Emanuele Borghesi, Maria Cittadini, Giuseppe De Carolis, Elena Drago, Enrico Bono, Valerio Pulzato, Ilaria Raiola, Anna Zappulo, Emanuela
Source	Medline; PMC
abstract	Diagnosis of invasive aspergillosis (IA) is challenging, particularly in high-risk patients with lung lesions other than typical according to 2008-EORTC/MSG criteria. Even if microbiology is positive, they still remain unclassified according to 2008-EORTC/MSG. Quantitative polymerase chain reaction (qPCR) provides new mycological documentation of IA. This retrospective study assessed Aspergillus fumigatus real time qPCR (MycoGENIE®) in BAL to diagnose IA and identify azole-resistant strains. Clinical, radiological, and microbiological data from 114 hematology patients (69% HSCT recipients; 29% on mould active agents) from years 2012-2017 were collected; and 123 BAL samples were tested with qPCR (cutoff: Ct < 40) and galactomannan (GM, Platelia®, cutoff: 0.5 ODI). Patients were classified as proven/probable, possible, and no-IA. %22Atypical-IA%22 referred to patients with lesions other than typical according to 2008-EORTC/MSG and positive mycology. Proven IA was diagnosed in two cases (1.6%), probable in 28 (22.8%), possible in 27 (22%), atypical in 14 (11.4%). qPCR was positive in 39 samples (31.7%). Sensitivity and specificity of qPCR for proven/probable IA (vs no-IA; atypical-IA excluded) were 40% (95% confidence interval [CI]: 23–59) and 69% (95%CI: 55–81), respectively. Sensitivity of qPCR was higher when combined with GM (83%, 95%CI: 65–94) and in those receiving mould-active agents at BAL (61%, 95%CI: 32–86). One sample had TR34/L98H mutation. In conclusion, in high-risk hematology patients with various lung lesions, A. fumigatus qPCR in BAL contributes to diagnosing IA, particularly if combined with GM and in patients receiving mould-active agents might allow detecting azole-resistant mutations in culture negative samples.
has issue date	2019-02-07(xsd:dateTime)
bibo:doi	10.1093/mmy/myz002
bibo:pmid	30753590
has license	no-cc
sha1sum (hex)	e5dffa0472ca1fbac398308c3242a11418dd7bc3
schema:url	https://doi.org/10.1093/mmy/myz002
resource representing a document's title	Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan
has PubMed Central identifier	PMC7107636
has PubMed identifier	30753590
schema:publication	Med Mycol
resource representing a document's body	covid:e5dffa0472ca1fbac398308c3242a11418dd7bc3#body_text
is schema:about of	named entity 'GALACTOMANNAN' named entity 'SAMPLES' named entity 'RESISTANT' named entity 'USE' named entity 'QPCR' named entity 'HEMATOLOGY' named entity 'LESIONS' named entity 'IDENTIFY' named entity 'DETECTING' named entity 'MICROBIOLOGY' named entity 'NEW' named entity 'OTHER THAN' named entity 'ACCORDING' named entity 'VARIOUS' named entity 'EORTC' named entity 'LUNG' named entity 'QUANTITATIVE POLYMERASE CHAIN REACTION' covid:arg/e5dffa0472ca1fbac398308c3242a11418dd7bc3 named entity 'ORIGINAL' named entity 'ASSESSED' named entity 'DOCUMENTATION' named entity 'SENSITIVITY' named entity 'RESISTANT' named entity 'PROVEN' named entity 'DATA' named entity 'AUTHOR' named entity '40%' named entity 'DIAGNOSIS' named entity 'CONCLUSION' named entity 'SENSITIVITY AND SPECIFICITY' named entity 'YEARS' named entity 'CUTOFF' named entity 'AZOLE' named entity 'POSITIVE' named entity 'UNCLASSIFIED' named entity 'PROBABLE' named entity 'CRITERIA' named entity 'REFERRED TO' named entity 'CASES' named entity 'PATIENTS' named entity 'CLASSIFIED' named entity 'FUMIGATUS' named entity 'HIGH-RISK' named entity 'ASPERGILLUS FUMIGATUS' named entity '114' named entity 'HSCT' named entity 'ALLOW' named entity 'SAMPLE' named entity 'RETROSPECTIVE STUDY' named entity 'CLINICAL' named entity 'MUTATION' named entity 'MYCOLOGICAL' named entity 'STRAINS' named entity 'CONFIDENCE INTERVAL' named entity 'PATIENTS' named entity 'COMBINED' named entity 'HIGHER' named entity 'ARTICLE' named entity 'BRONCHOALVEOLAR LAVAGE' named entity 'USE OF' named entity 'COMBINED' named entity 'AZOLE' named entity 'INCLUDING' named entity 'FOR DIAGNOSIS' named entity 'CASES' named entity 'ASPERGILLUS FUMIGATUS' named entity 'NEED FOR' named entity 'POSSIBLE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software